shingles on the left side of her face, inner eye, throat, ear, and neck/herpes zoster ophthalmicus; postherpetic neuralgia; This literature-non-study case was reported in a literature article and describes the occurrence of OPHTHALMIC HERPES ZOSTER (shingles on the left side of her face, inner eye, throat, ear, and neck/herpes zoster ophthalmicus) in a 51-year-old female patient who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.       The patient's past medical history included Chickenpox (As child) and Deep vein thrombosis. Concurrent medical conditions included Atrial fibrillation, Hypothyroidism and Endometriosis.   On an unknown date, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced OPHTHALMIC HERPES ZOSTER (shingles on the left side of her face, inner eye, throat, ear, and neck/herpes zoster ophthalmicus) (seriousness criterion medically significant). an unknown date, the patient experienced POST HERPETIC NEURALGIA (postherpetic neuralgia). The patient was treated with VALACYCLOVIR [VALACICLOVIR] at an unspecified dose and frequency; GABAPENTIN at a dose of UNK, as necessary and PREDNISONE (oral) at a dose of UNK (taper). At the time of the report, OPHTHALMIC HERPES ZOSTER (shingles on the left side of her face, inner eye, throat, ear, and neck/herpes zoster ophthalmicus) was resolving and POST HERPETIC NEURALGIA (postherpetic neuralgia) had not resolved.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered OPHTHALMIC HERPES ZOSTER (shingles on the left side of her face, inner eye, throat, ear, and neck/herpes zoster ophthalmicus) and POST HERPETIC NEURALGIA (postherpetic neuralgia) to be related.    The patient did not have diabetes mellitus or any other known immunodeficiency.  No concomitant medications were reported.  The patient was presented to an outpatient dermatology clinic due to a rash on face and left eyelid.  The rash was blistering, burning, and severe. The rash was present for two weeks. The patient also experienced chills, fever, and a sore throat for three days. One week after receiving the 1st vaccination, the patient broke out with shingles on the left side of her face, inner eye, throat, ear, and neck.  The patient was advised to take valacyclovir until after the second COVID-19 vaccine and gabapentin as needed. After receiving the second dose of the COVID-19 vaccine, the patient experienced an immediate shingles reaction despite taking valacyclovir.  Shingles affected the left eye, face, scalp, ear, neck, and throat. The patient had little immediate relief from valacyclovir or oral prednisone taper. Over the next three months, the patient experienced resolution of skin lesions with fading hyperpigmentation still present, however, the patient was still experiencing pain in the V1. Patient also suffered from herpes zoster ophthalmicus and experienced postherpetic neuralgia.   Authors concluded that the patient experienced all the complications despite receiving prompt antiviral therapy. While the value of vaccines and the value of the COVID-19 vaccine has been well demonstrated, it is important to consider and document vaccine-related complications.   Most recent FOLLOW-UP information incorporated above includes: On 04-May-2023: Follow up received by safety on 05-May-2023 has email with full text article and contains significant information. Reporter information, literature citation details, relevant medical history, treatment medications, event details and data updated.  Company Comment: This literature-non-study case concerns a 51-year-old female patient, who had chickenpox as a child, whit no history of immunodeficiency, who experienced the unexpected and serious (due to medically significant) event Ophthalmic herpes zoster (2 episodes), which occurred after the first and the second dose of mRNA-1273 vaccine. As reported, 1 week after the first dose of mRNA-1273 vaccine, the patient broke out with shingles on the left side of her face, inner eye, throat, ear, and neck. She also experienced chills, fever, and a sore throat for three days.The rash was blistering, burning and severe, and was present for 2 weeks, until patient went to an outpatient dermatology clinic. She was advised to take valacyclovir until after the second COVID-19 vaccine and gabapentin as needed. After receiving the second dose of the mRNA-1273 vaccine, she experienced an immediate shingles reaction despite taking valacyclovir, that affected the left eye, face, scalp, ear, neck, and throat. The patient had little immediate relief from valacyclovir or oral prednisone taper. Over the next three months, the patient experienced resolution of skin lesions with fading hyperpigmentation still present, however, she was still experiencing pain in the V1 distribution, consistent with postherpetic neuralgia. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This literature-non-study case concerns a 51-year-old female patient, who had chickenpox as a child, whit no history of immunodeficiency, who experienced the unexpected and serious (due to medically significant) event Ophthalmic herpes zoster (2 episodes), which occurred after the first and the second dose of mRNA-1273 vaccine. As reported, 1 week after the first dose of mRNA-1273 vaccine, the patient broke out with shingles on the left side of her face, inner eye, throat, ear, and neck. She also experienced chills, fever, and a sore throat for three days.The rash was blistering, burning and severe, and was present for 2 weeks, until patient went to an outpatient dermatology clinic. She was advised to take valacyclovir until after the second COVID-19 vaccine and gabapentin as needed. After receiving the second dose of the mRNA-1273 vaccine, she experienced an immediate shingles reaction despite taking valacyclovir, that affected the left eye, face, scalp, ear, neck, and throat. The patient had little immediate relief from valacyclovir or oral prednisone taper. Over the next three months, the patient experienced resolution of skin lesions with fading hyperpigmentation still present, however, she was still experiencing pain in the V1 distribution, consistent with postherpetic neuralgia. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.